Results 141 to 150 of about 43,753 (252)

Targeting Krebs-cycle-deficient renal cell carcinoma with Poly ADP-ribose polymerase inhibitors and low-dose alkylating chemotherapy. [PDF]

open access: yesOncotarget, 2022
Ueno D   +17 more
europepmc   +1 more source

Olaparib‐associated cutaneous vasculitis in a patient with breast cancer

open access: yes
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Marcial Álvarez‐Salafranca   +3 more
wiley   +1 more source

Tumor Infiltrating Lymphocyte Therapy Combined With PD‐1/LAG‐3 Inhibition in Patients With Recurrent Platinum‐Resistant Ovarian Cancer

open access: yesInternational Journal of Cancer, Volume 159, Issue 7, Page 1735-1749, 1 October 2026.
The detection of tumor‐infiltrating lymphocytes (TILs) is a positive prognostic factor in ovarian cancer. Moreover, TILs are significantly boosted by immunotherapy, though ovarian cancer patients have seen limited benefit from immune therapies. This study investigated the safety and feasibility of TIL therapy combined with PD‐1 and LAG‐3 inhibitors in ...
Tine J. Monberg   +9 more
wiley   +1 more source

PARP (Poly ADP-Ribose Polymerase) inhibitors for locally advanced or metastatic breast cancer. [PDF]

open access: yesCochrane Database Syst Rev, 2021
Taylor AM   +6 more
europepmc   +1 more source

Cinnamaldehyde From Cinnamon as a Food‐Derived Bioactive: Phytochemistry, Anticancer Mechanisms, Bioavailability, Nanoformulation and Safety

open access: yesFood Frontiers, Volume 7, Issue 5, September 2026.
Cinnamaldehyde derived from Cinnamomum species exerts multitarget anticancer effects by promoting oxidative stress, mitochondrial dysfunction, apoptosis, cell‐cycle arrest, autophagy, and epigenetic changes, and by suppressing mitogen‐activated protein kinase (MAPK), phosphoinositide 3‐kinase/protein kinase B/mechanistic target of rapamycin (PI3K/Akt ...
Gervason Moriasi   +6 more
wiley   +1 more source

Cyclins and Cyclin‐Dependent Kinases: Structure, Biological Functions, and Innovative Targeting Strategies in Cancer

open access: yesMedComm, Volume 7, Issue 9, September 2026.
This work synthesizes recent insights into the pathological roles of cyclins and cyclin‐dependent kinases (CDKs) across human cancers, highlights state‐of‐the‐art innovative approaches (especially targeted degradation and redistribution of CDK/cyclin proteins) for cancer therapy, and outlines future directions for CDK/cyclin‐related biomedical research.
Suya Zheng   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy